AN OBSERVATIONAL PROPENSITY SCORE-MATCHED STUDY TO EVALUATE COST-EFFECTIVENESS OF A REAL-TIME PCR-BASED ASSAY IN PATIENTS WITH SUSPECTED SEPSISK
Author(s)
Zaniolo O1, Povero M1, Pradelli L1, Pizzorno B2, Mancini N3
1AdRes HE&OR, Turin, Italy, 2Roche Diagnostics, Monza, Italy, 3Università Vita e Salute, Milano, Italy
OBJECTIVES Although the real-time PCR-based assay SeptiFast® has proven its utility in different clinical settings, limited data are still available on its economic performance. An Italian two-center observational study was conducted on hematological patients with signs of SIRS-SS (Systemic Inflammatory Response Syndrome with Suspected Sepsis) in order to partially fill this information gap. METHODS RESULTS A total of 101 pairs of highly matched SIRS-SS episodes have been formed. Prospective cohort shows a non-significant trend to a lower mortality (8.24% vs. 13.48%). Under more stringent matching condition (77 pairs), episodes experienced by prospective patients are associated to a significantly lower mortality (3.13% vs 14.71%). No significant differences in the average LOSE are recorded. Traditional diagnostic assays cost is €152 lower in the prospective cohor; however, this saving is completely offset by the cost of the PCR assay. The greatest saving related to the use of PCR assay is linked to the hard reduction in the empirical therapy (€488.44 per episode), main driver of the overall saving (€430.73 per episode), which results statistically significant. CONCLUSIONS These findings suggest that the routine use of combined traditional and PCR diagnostic assays may conduct to an early saving of broad-spectrum antibiotics, money, and health.
Conference/Value in Health Info
2014-11, ISPOR Europe 2014, Amsterdam, The Netherlands
Value in Health, Vol. 17, No. 7 (November 2014)
Code
PIN52
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Infectious Disease (non-vaccine)